About PRI
  Research at PRI
  ICOC Conference
  RAHMS Conference
  Contact PRI

Several PRI studies have been published in a number of international journals including:


Biomarkers and Environment
Drugs of Today

Journal of Radioanalytical and Nuclear Chemistry

SOSTE Notiziario

Transfusion Science

Other publications by PRI members

back to PRI publications
Publications by George J Kontoghiorghes:

Maher P, Kontoghiorghes GJ. (2015)
Characterization of the Neuroprotective Potential of Derivatives of the Iron Chelating Drug Deferiprone.
Neurochemical Research 2015;40:609-620

Timoshnikov VA, Kobzeva TV, Polyakov NE, Kontoghiorghes GJ. (2015)
Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.
Free Radicals Biology and Medicine 78:118-122.

Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. (2014)
Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.
World Journal of Methodology 4:197-218

Timoshnikov VA, Klimentiev VI, Polyakov NE, Kontoghiorghes GJ (2014)
Photoinduced transformation of iron chelator deferiprone: Possible implications in drug metabolism and toxicity.
Journal of Photochemistry and Photobiology A: Chemistry 289:14-21

Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. (2014)
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.
World Journal of Methodology 4:163-188

Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ. (2014)
Antioxidant targeting by deferiprone in diseases related to oxidative damage.
Frontiers Bioscience (Landmark Ed). 19:862-85.

Kontoghiorghes G J (2013)
Turning a blind eye to deferasirox's toxicity?
Lancet 381 (9873): 1183-1184

Kontoghiorghes G J (2013)
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Expert Opin Drug Saf. 2013;12:605-609

Kontoghiorghes G J (2013)
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Author's response.
Expert Opin Drug Saf. 2013;12: 794-795

Kontoghiorghes GJ. (2013)
The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
Toxicol Mech Methods. 23 (1) :1-4.

Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ. (2013)
Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Toxicol Mech Methods. 23(1):48-56.

Born T, Kontoghiorghe CN, Spyrou A, Kolnagou A, Kontoghiorghes GJ. (2013)
EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
Toxicol Mech Methods. 23(1):11-17.

Kolnagou A, Michaelides Y, Kontoghiorghe CN, Kontoghiorghes GJ. (2013)
The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.
Toxicol Mech Methods. 23(1):34-41

Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ (2013)
Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.
Expert Opin Investig Drugs. 22:591-618

Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ. (2012)
Iron mobilization using chelation and phlebotomy.
J Trace Elem Med Biol. 26 (2-3):127-130.

Kontoghiorghes GJ. (2011)
The proceedings of the 19th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.
Hemoglobin. 35(3):181-185.

Kolnagou A, Kleanthous M, Kontoghiorghes GJ. (2011)
Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Hemoglobin. 35(3):186-198.

Konstantinou E, Pashalidis I, Kolnagou A, Kontoghiorghes GJ. (2011)
Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategies.
Hemoglobin. 35(3):237-246.

Kontoghiorghes GJ. (2011)
A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.
Hemoglobin. 35(3):301-311.

Kolnagou A, Kontoghiorghes GJ (2010)
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
Br J Haematol.2010 150(4):489-90.

Kolnagou A, Kontoghiorghes GJ (2010)
Future challenges in the use of magnetic resonance imaging for the diagnosis of iron overload.
Blood Transfusion 8(4):309-10.

Kolnagou A, Kleanthous M, Kontoghiorghes GJ (2010)
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Eur J Haematol. 85(5):430-8

Kontoghiorghes GJ (2010)
Introduction of higher doses of deferasirox: Better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Expert Opinion in Drug Safety 9(4):633-641.

Kontoghiorghes GJ (2010)
The 18th ICOC proceedings in Athens, Greece: new breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy.
Hemoglobin. 34(3):199-203

Kontoghiorghes G J, Spyrou A, Kolnagou A (2010)
Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Hemoglobin. 34(3):251-264

Kontoghiorghes G J, Kolnagou A, Skiada A, Petrikkos G (2010)
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Hemoglobin. 34(3):227-239

Kolnagou A, Kontoghiorghes GJ (2010)
Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Hemoglobin. 34(3):204-209.

Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A (2010).
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
Expert Opinion on Drug Safety 9(2):201-6.

Kontoghiorghes GJ (2009)
The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Hemoglobin 33 (5):283-6.

Kolnagou A, Kontoghiorghes GJ (2009)
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Hemoglobin. 33(5):287-95.

Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ (2009).
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Hemoglobin. 33(5):312-22

Kontoghiorghes GJ (2009)
A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Hemoglobin. 33(5):332-8

Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A (2009).
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Hemoglobin. 33(5):386-97.

Kontoghiorghes G J.
Prospects for introducing deferiprone as potent pharmaceutical antioxidant.
Frontiers Bioscience 2009; E1: 161-78.

Kontoghiorghes G J.
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Expert Opinion Drug Safety 2008; 7(6):1-2.

Kontoghiorghes G J.
Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide.
Hemoglobin 2008; 32: 608 - 615.

Kontoghiorghes GJ, Efstathiou A, Ioannou-Loucaides S, Kolnagou A.
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
Hemoglobin. 2008;32:217-227.

Fukuda S, Ikeda M, Nakamura M, Katoh A, Yan X, Xie Y, Kontoghiorghes GJ.
The effects of bicarbonate and its combination with chelating agents used for the removal of depleted uranium in rats.
Hemoglobin. 2008;32:191-198.

Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Hemoglobin. 2008;32:41-47.

Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone.
Hemoglobin. 2008;32:17-28.

Kontoghiorghes GJ.
Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/Deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox.
Hemoglobin. 2008;32:1-15.

Kontoghiorghes G J.
Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.
Expert Opin. Drug Saf. (2007) 6(3):235-239.

Kontoghiorghes G J, Kolnagou A.
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Haematologica 2006; 91:(ELT) 04.

Kontoghiorghes G J.
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Hemoglobin 2006; 30:329-347.

Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes G J.
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. the importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Hemoglobin 2006; 30: 219-227.

Kolnagou A, Kontoghiorghes G J.

Effective combination therapy of deferiprone and desferrioxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. the protocol of the international committee on oral chelators.
Hemoglobin 2006; 30: 239-249.

Kontoghiorghes G J.
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Hemoglobin 2006;30:183-200.

Fukuda S, Ikeda M, Anzai K, Suzuki M, Katoh A, Kontoghiorghes G J.
Radiation protection by deferiprone in animal models.
Hemoglobin 2006; 30: 201-208.

Kontoghiorghes GJ.
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Expert Opin Emer Drugs. 2006; 11: 1-5.

Peng CT, Fucharoen S, Kontoghiorghes GJ, Tsai CH.
Report on the Proceedings of the 15(th) International Conference on Oral Chelation (ICOC) in the Treatmentof Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
Hemoglobin. 2006; 30: 63-68.

Kontoghiorghes GJ.
Effects of ICL670 (deferasirox) on cardiac iron concentrations.
Lancet. 2005; 366:804.

Kontoghiorghes GJ, Kolnagou A, Eracleous E, Evans RW.
Iron mobilisation from transferrin by deferiprone (L1).
Br J Haematol. 2005; 129:157

Kontoghiorghes GJ.
New oral iron-chelating drugs for the treatment of transfusional iron overload and other diseases.
Drugs Future. 2005; 30: 1241-51.

Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
Advances in iron overload therapies. Prospects for effective use of deferiprone(L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations.
Curr Med Chem. 2005; 12: 2663-81.

Kontoghiorghes GJ, Kolnagou A.
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators.
Curr Med Chem. 2005; 12: 2695-710.

Kontoghiorghes GJ.
Regulatory molecules and chelators used for the control of essential and toxic metals in health and disease: From molecular interactions to clinical effects and applications.
Curr Med Chem. 2005; 12: 2661-2.

Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ.
Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia.
Brit J Haematol. 2004; 127:360-1.

Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A.
The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
Curr Med Chem. 2004;11:2161-83

Kontoghiorghes GJ.
Do we need more iron chelating drugs.
Lancet. 2003; 362: 495-6.

Kontoghiorghes GJ, Neocleous K, Kolnagou A.

Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine.
Drug Saf.  2003; 26: 553-84.

Kontoghiorghes GJ, Kolnagou A.
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Lancet. 2003; 361:184.

Douvas GS, May MH, Kolnagou A, Kontoghiorghes G J.
Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.
Arzneimittelforschung. 2002;52:45-52.

Kontoghiorghes GJ.
Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.
Drugs Today (Barc). 2001 ;37:23-35.

Pashalidis I and Kontoghiorghes GJ.
Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II).
Arzneimittel-Forschung / Drug Research 2001, Volume 51 (II), pages 998-1003

Kontoghiorghes GJ.
Clinical use, therapeutic aspects and future potential of deferiprone in thalassaemia and other conditions of iron and other metal toxicity.
Drugs of Today 2001, Volume 37, pages 23-35

Pashalidis I and Kontoghiorghes GJ.
Interaction of L1-Deferiprone with Cu(II) and U(VI) ions. Chemical characterisation of solid phases and possible clinical application.
Biomarkers and Environment 2001, Volume 4 (suppl 1), pages 80-81

Kontoghiorghes GJ, Sitarou M, Pattichi K and Kolnagou A.
Iron overload toxicity and new therapeutic strategies with the orally effective chelating drug deferiprone (L1).
Biomarkers and Environment 2001, Volume 4 (suppl 1), pages 16-21

Kontoghiorghes GJ, Agarwal MB, Grady RW, Tondury P and Marx JJ.
Deferiprone or fatal iron toxic effects?.
Lancet 2001, Volume 357, pages 882-883.

Kontoghiorghes GJ, Sitarou M, Pattichis K, Hadjigavriel M and Kolnagou A.
Present status and future prospects of oral chelation with L1-deferiprone and other orally active chelators.
SO.S.T.E. Notiziario 2001, Volume 2 (1), pages 98-101

Kontoghiorghes GJ, Agarwal MB, Grady RW, Kolnagou A and Marx JJ.
Deferiprone for thalassaemia.
Lancet 2000, Volume 356, pages 428-429.

Pashalidis I and Kontoghiorghes GJ.
Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications.
Transfusion Science 2000, Volume 23, pages 259-261.

Kontoghiorghes GJ, Pattichi K, Hadjigavriel M and Kolnagou A.
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Transfusion Science 2000, Volume 23, pages 211-223.

Paschalidis I and Kontoghiorghes GJ.
Effective complex formation in the interaction of 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with uranium(VI).
Journal of Radioanalytical and Nuclear Chemistry 1999, Volume 242, pages 181-184.

Eybl V, Kotyzova D, Koutensky J, Migkova V, Sykora J and Kontoghiorghes GJ.
The influence of deferiprone (L1) and deferoxamine on the level of essential elements in mice.
Biomarkers and Environment 1999, Volume 3, pages 25-28.

Wong A, Alder V, Robertson D, Papadimitriou J, Maserei J, Berdoukas V, Kontoghiorghes G, Taylor E, Baker E.
Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
Biometals. 1997 ;10:247-56.

Kontoghiorghes GJ.
Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
Arch Toxicol Suppl. 1996;18:202-14.

Kontoghiorghes GJ, Bunce T, Bruckdorfer KR
Defferentiation of the therapeutic and toxicological effects of iron and copper chelating drugs in relation to free radical toxicity.
Toxicol Lett. 1995; 78:48-9.

Jeremy JY, Gill J, Kontoghiorghes GJ
Copper chelators inhibit platelet thromboxane A2 synthesis and lipoxygenase activity in vitro.
J Dr Dev Clin Prac 1995;7: 119-21.

Kontoghiorghes GJ, Sheppard L, Bartlett L, Bruckdorfer KR, Evans RW
Factors affecting the efficacy and toxicity of Deferiprone (L1) in transfusional iron loaded patients. In: Beuzard Y, Lubin B, Rosa J (eds). "Sickle cell disease and thalassaemia: New trends in therapy".
Colloque INSERM/John Libbey Eurotext . 1995; 234: 363-65.

Kontoghiorghes GJ.
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Toxicol Lett. 1995 ;80:1-18.

Kontoghiorghes GJ, Weinberg ED.
Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches.
Blood Rev. 1995 ;9:33-45.

Kontoghiorghes GJ.
New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators.
A review. Analyst. 1995 ;120:845-51.

Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P.
Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Arzneimittelforschung. 1995 ;45:65-9.

Kontoghiorghes GJ, Barr J, Baillod RA.
Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Arzneimittelforschung. 1994 ; 44:522-6.

Kontoghiorghes GJ.
Compliance with iron-chelation treatment after bone marrow transplantation.
Lancet. 1994 ;343:604-5.

Kontoghiorghes GJ.
Therapeutic, pharmacological and toxicological aspects of metals and new chelating drugs.
Cur Topics Molec Pharmac.1993; 1: 189-211.

Kontoghiorghes GJ.
Misinformation about deferiprone (L1).
Lancet. 1993 ; 342:250.

Kontoghiorghes GJ.
Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
Indian J Pediatr. 1993;60:485-507.

Kontoghiorghes GJ, Agarwal MB, Tondury P, Kersten MJ, Jaeger M, Vreugdenhil G, Vania A, Rahman YE.
Future of oral iron chelator deferiprone. (L1) ICOC committee.
Lancet. 1993 ;341:1479-80.

Sheppard LN, Kontoghiorghes GJ.
Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
Arzneimittelforschung. 1993;43:659-63.

Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L.
Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
Am J Hematol. 1993 ; 42:340-9.

al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.
Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
Br J Haematol. 1992 ;82:431-6.

al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ.
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
Blood. 1992 ; 80:593-9.

Ganeshaguru K, Lally JM, Piga A, Hoffbrand AV, Kontoghiorghes GJ.
Cytotoxic mechanisms of iron chelators.
Drugs Today (Barc) 1992; 28 (A): 29-34.

Sheppard LN, Kontoghiorghes GJ.
Synthesis and metabolism of L1 and other novel alpha-ketohydroxypyridine iron chelators and their metal complexes.
Drugs Today (Barc) 1992; 28 (A): 3-10.

Nortey P, Barr J, Matsakis M, Nasseri-Sina P, Kontoghiorghes GJ.
Effect on iron excretion and animal toxicology of L1 and other alpha-ketohydroxypyridine chelators.
Drugs Today (Barc). 1992; 28(A): 81-8.

Evans RW, Sharma M, Ogwand W, Patel KJ, Bartlett AN, Kontoghiorghes GJ.
The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo.
Drugs Today (Barc). 1992; 28(A): 19-23.

Mastrandrea S, Carvajal JL, Kaeda JS, Kontoghiorghes GJ, Luzzato L.
Growth inhibition of Plasmodium Falciparum by orally active iron chelators.
Drugs Today (Barc). 1992; 28 (A): 25-7.

Jeremy JY, Gill J, Prior T, Sifaksi G. Barradas MA, Kontoghiorghes GJ.
Inhibition of cycloxygenase and lipoxygenase activity by iron chelators:possible use in the treatment of eicosanoid-related disorders.
Drugs Today (Barc). 1992; 28 (A): 35-43.

Tondury P, Wagner HP, Kontoghiorghes GJ.
Update of long term clinical trials with L1 in beta-thalassaemia major patients in Berne, Switzerland.
Drugs Today (Barc) 1992. 28(A):115-7.

Hoffbrand AV, Kontoghiorghes GJ.
Protocol for monitoring efficacy and toxicity in clinical trials with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1).
Drugs Today (Barc). 1992; 28(A): 149-55.

Eybl V, Svihovcova P, Koutensky J, Kontoghiorghes GJ.
Interaction of L1, L1NAll and desferoxamine with Gallium in vivo.
Drugs Today (Barc). 1992; 28(A): 173-5.

Volf V, Kontoghiorghes GJ.
Retention of injected plutonium and americium in mice and rats after oral treatment with DTPA, desferrioxamine and α-ketohydroxypyridines.
Drugs Today (Barc). 1992; 28(A): 169-72.

Kontoghiorghes GJ, Sheppard L, Barr J, Baillod R.
Aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1).
Drugs Today (Barc) 1992;28:Suppl.A:183-7.

Kontoghiorghes GJ.
Advances in oral iron chelation in man.
Int J Hematol. 1992; 55 :27-38.

Sheppard L and Kontoghiorghes GJ.
Comparative iron binding studies of bis and tris (3-hydroxy-2-methylpyrid-4-ones) and desferrioxamine.
Inorg Chim Acta 1991; 188: 177-83.

Kontoghiorghes GJ.
Oral iron chelation is here.
BMJ. 1991 23; 303:1279-80.

Kontoghiorghes G.
In vivo testing of oral iron chelators intended for clinical use.
Blood. 1991;78:535-7.

Vreugdenhil G, Kontoghiorghes GJ, Van Eijk HG, Swaak AJ.
Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Clin Exp Rheumatol. 1991; 9:35-40.

Eybl V, Caisova D, Koutensky J, Kontoghiorghes GJ.
Influence of iron chelators, 1,2-dialkyl-3-hydroxypyridin-4-ones, on the lipid peroxidation and glutathione level in the liver of mice.
Arch Toxicol Suppl. 1991;14:185-7.

Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP.
L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
Br J Haematol. 1990 ;76:550-3.

Kontoghiorghes GJ.
Chelators affecting iron absorption in mice.
Arzneimittelforschung. 1990 ;40:1332-5.

Jordan D, Kontoghiorghes G.
Blood disorders: future trends in iron chelation.
Nurs Stand. 1990 ;5:25-7.

Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ.
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.
Br J Haematol. 1990 ;76:301-4.

Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P.
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Br J Haematol. 1990 ;76:295-300.

Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L.
Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Clin Pharmacol Ther. 1990 ;48:255-61.

Brock JH, Liceaga J, Arthur HM, Kontoghiorghes GJ.
Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Am J Hematol. 1990 ;34:21-5.

Goddard JG, Kontoghiorghes GJ.
Development of an HPLC method for measuring orally administered 1-substituted-2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids.
Clin Chem. 1990 ;36:5-8.

Kontoghiorghes GJ.
Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia.
Ann N Y Acad Sci. 1990; 612:339-50.

Kontoghiorghes GJ, May A.
Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells.
Biol Met. 1990;3:183-7.

Kontoghiorghes GJ
Drugs Fut (Barc) 1990;15:230-2.

Kontoghiorghes GJ, Hoffbrand AV.
Clinical trials with oral iron chelator L1.
Lancet. 1989 ;2:1516-7.

Vreugdenhil G, Swaak AJ, Kontoghiorghes GJ, van Eijk HG.
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.
Lancet. 1989 ;2:1398-9.

Kontoghiorghes GJ, Nasseri-Sina P, Goddard JG, Barr JM, Nortey P, Sheppard LN.
Safety of oral iron chelator L1.
Lancet. 1989 ;2:457-8.

Hoffbrand AV, Bartlett AN, Veys PA, O'Connor NT, Kontoghiorghes GJ.
Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.
Lancet. 1989 ;2:457.

Blatt J, Taylor SR, Kontoghiorghes GJ.
Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines.
Cancer Res. 1989 ;49:2925-7.

Barradas MA, Jeremy JY, Kontoghiorghes GJ, Mikhailidis DP, Hoffbrand AV, Dandona P.
Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity.
FEBS Lett. 1989 ;245:105-9.

Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV.
Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.
Prog Clin Biol Res. 1989; 309:107-14.

Kontoghiorghes GJ
L1 (1,2-dimethyl-3-hydroxypyrid-4-one).
Drugs Fut (Barc) 1988; 13: 413-5.

Kontoghiorghes GJ
Structure/red blood cell permeability activity of iron (III) chelator complexes.
Inorg Chim Acta: 1988; 151:101-6.

Kontoghiorghes GJ, Sheppard L, Barr J.
Synthetic methods and in vitro iron binding studies of the novel 1-alkyl-2-ethyl-3-hydroxypyrid-4-ones.
Inorg Chim Acta 1988; 152: 195-9.

Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P.
The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
Biochem J. 1988 ;254:239-44.

Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton JW.
Antimalarial properties of orally active iron chelators.
Blood. 1988 ;72:358-61.

Kontoghiorghes GJ.
Iron chelating drugs.
Br Med J . 1988 ;296:1672-3.

Kontoghiorghes GJ.
New orally active alpha-ketohydroxy pyridine chelators for the treatment of iron overload.
Birth Defects Orig Artic Ser. 1988;23:97-103.

Brock JH, Liceaga J, Kontoghiorghes GJ.
The effect of synthetic iron chelators on bacterial growth in human serum.
FEMS Microbiol Immunol. 1988 ;1:55-60.

Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L.
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Br Med J . 1987 ; 295:1509-12.

Forsbeck K, Nilsson K, Kontoghiorghes GJ.
Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexes.
Eur J Haematol. 1987 ;39:318-25.

Kontoghiorghes GJ, Sheppard L, Chambers S.
New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.
Arzneimittelforschung. 1987;37:1099-102.

Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV.
1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Lancet. 1987 ;1:1294-5.

Kontoghiorghes GJ.
2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation,
Biochim Biophys Acta. 1987 ;924:13-8.

Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
J Clin Pathol. 1987 ;40:404-8.

Kontoghiorghes GJ.
The effect of 2,4-dihydroxypyridine-N-oxide, a new orally active iron chelator, on iron excretion in mice.
Clin Chim Acta. 1987 ;163:137-41.

Kontoghiorghes GJ, Chambers S, Hoffbrand AV.
Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.
Biochem J. 1987;241:87-92.

Mostert LJ, Van Dorst JA, Koster JF, Van Eijk HG, Kontoghiorghes GJ.
Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte.
Free Radic Res Commun. 1987; 3:379-88.

Kontoghiorghes GJ.
Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.
Acta Haematol. 1987;78:212-6.

Kontoghiorghes GJ.
Decrease solubilisation of ferritin iron and fresh iron (III) precipitate following repeated chelator treatments.
Inorg Chim Acta. 1987:138: 36-40.

Kontoghiorghes GJ.
Iron Chelation in Biochemistry and Medicine.
In: Free Radicals Oxidant Stress and Drug Action. (Ed. C. Rice-Evans) pp 1987: 277-303, Richelieu Press, London.

Kontoghiorghes GJ.
Structure/iron binding activity of 1-hydroxypyrid-2-one chelators intended for clinical use.
Inorg Chim Acta 1987;135: 145-50.

Kontoghiorghes GJ. & Sheppard L.
Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones.
Inorg Chim Acta 1987; 136: L11-L12.

Kontoghiorghes GJ.
Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
Mol Pharmacol. 1986 ;30:670-3.

Kontoghiorghes GJ, Piga A, Hoffbrand AV.
Cytotoxic effects of the lipophilic iron chelator omadine.
FEBS Lett. 1986;204:208-12.

Kontoghiorghes GJ.
Dose response studies using desferrioxamine and orally active chelators in a mouse model.
Scand J Haematol. 1986 ;37:63-70.

Kontoghiorghes GJ, Piga A, Hoffbrand AV.
Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines.
Hematol Oncol. 1986 ;4:195-204.

Kontoghiorghes GJ.
Iron mobilisation from lactoferrin by chelators at physiological pH.
Biochim Biophys Acta. 1986 ;882:267-70.

Kontoghiorghes GJ, Hoffbrand AV.
Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
Br J Haematol. 1986 ; 62:607-13.

Kontoghiorghes GJ.
The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.
Biochim Biophys Acta. 1986 ;869:141-6.

Kontoghiorghes GJ.
Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators.
Biochem J. 1986 ;233:299-302.

Kontoghiorghes GJ, Jackson MJ, Lunec J.
In vitro screening of iron chelators using models of free radical damage.
Free Radic Res Commun. 1986;2:115-24.

Rice-Evans C, Baysal E, Flynn E, Kontoghiorghes GJ.
Iron Mediated free radical effect on erythrocytes: the role of desferrioxamine.
Bioch Soc Trans 1986;14: 368-9.

Rice-Evans C, Baysal E, Flynn D, Kontoghiorghes GJ.
The effects of desferrioxamine and ascorbate on haemoglobin from thalassaemia Erythrocytes.
Biomedical Science Reports. Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine. (Ed. Rotilio G). pp 1986: 662-6. Elsevier Pub.

Taylor DM, Kontoghiorghes GJ.
Mobilisation of plutonium and iron from transferrin and ferritin by α-oxohydroxypyridine chelators.
Inorg Chim Acta: 1986; 125:L35-L38.

Kontoghiorghes GJ, Evans RW.
Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators.
FEBS Lett. 1985 ;189:141-4.

Kontoghiorghes GJ.
New orally active iron chelators.
Lancet. 1985 ;1:817.

Rice-Evans C, Baysal E, Kontoghiorghes GJ, Flynn DM, Hoffbrand AV.
Oxidative effects of iron on erythrocytes.
Free Radic Res Commun. 1985;1:55-62.

Kontoghiorghes GJ, Keast CG.
A simple metabolic cage for mice.
Laboratory practice. 1984; 33: 90-1.

Kontoghiorghes G, Marcus RE, Huehns ER.
Desferrioxamine suppositories.
Lancet. 1983; 2:454.

Kontoghiorghes GJ, Wilson MT.
Structural and kinetic studies on eisenia foetida erythrocruorin.
In:Invertebrate Oxygen Binding Proteins, Structure, Active Site and Function (Ed J Lamy and J Lamy). 1981:385-91. Marcel Dekker, New York and Basel.



Best viewed with
Internet Explorer
at 800 x 600 or higher
Last update:
24 January 2006

POSTGRADUATE RESEARCH INSTITUTE Science, Technology, Environment and Medicine
3 Ammochostou Street, CY-3021 Limassol, Cyprus
Postal address: P.O. Box 51342, CY-3504 Limassol, Cyprus
Tel: +357 25 734 615, Fax: +357 25 395 926, Email:
About PRIResearch at PRI  |  Publications  |  Deferiprone  |  Conferences  |  Sponsors  |  Contact PRI
  Copyright © 2002-2006 Postgraduate Research Institute


Designed by LabWell Research Laboratories